Orally administered vaccine can protect millions from hepatitis B. Oral vaccines are both safer and less expensive than injections. Therefore, researchers are continuously pursuing ways to produce an oral vaccine that is sufficiently effective. Now, University of Copenhagen physicists have delivered virologists a “recipe” for improving vaccine drops using methods from the world of nanophysics.
Millions of people are infected with hepatitis B every year. Hundreds of thousands die. And small children are particularly at risk. Due to high cost and the stable environmental conditions required for vaccine storage, many people in developing countries are not vaccinated against this dangerous virus. As such, researchers have been working to produce a drop or powdered form of oral vaccine. Oral vaccinations are cheaper and more easily administered than injections. However, developing a sufficiently effective oral hepatitis B vaccine has so far eluded researchers.
A joint collaboration from physicists at the Niels Bohr Institute, a team of researchers from University of São Paulo together with the Butantan Institute has introduced a technique to the pharmaceutical world that just might do the trick and lead to an optimal oral Hepatitis B vaccine.
“We have used a technology commonly used in solid state physics to explore how the vaccine behaves within a particular type of encapsulation. This has yielded crucial information that would not otherwise have been achievable. When we scientists venture beyond our comfort zone and deploy each other’s knowledge across disciplines, entirely new possibilities can emerge,” says Heloisa Bordallo, an associate professor at the Niels Bohr Institute, and one of the two main authors of the research article just published in Scientific Reports.
Three dimensional insight
A major challenge of making an oral vaccine is to encapsulate it in a material that can endure the harsh conditions of our digestive system, to protect the vaccine from being destroyed before it reaches its intended destination in the body. The Danish research team’s collaborative partners in Brazil have long known that the silica-material SBA-15 is well-suited to encapsulate a hepatitis B vaccine. However, they did not know exactly how the material protected the vaccine. Nor were they certain about why their vaccine was not always completely effective.
This is where the team of Danish physicists came into the picture. Using a special technique that combines x-ray and neutron imaging, researchers at the Niels Bohr Institute were able to produce 3D images of the inside of the SBA-15 silica. It marked a crucial step in the use of this technique to develop pharmaceuticals. The imagery allows researchers to see how the vaccine behaves inside the silica, right down to the particle scale. Among other things, they were able to see that the vaccine had a tendency to clump within the silica, making it less effective.
“Now we know what makes the vaccine less effective, and how to optimize it. We know exactly how much vaccine should be put in the silica capsule for it to work best in the body and the clinical trials can be better interpreted,” explains Heloisa Bordallo.
No more swelling and inflammation
The vaccine is particularly promising for developing nations, explains the other main author, Martin K. Rasmussen, a former student at the Niels Bohr Institute and current doctoral student at DTU:
“Getting rid of needles being poked into the arms of little children is an advantage in and of itself. It also eliminates any need to sterilize needles and possible side effects such as swelling and infection. And, unlike the vaccine in use today, this type of vaccine needn’t be refrigerated. As such, costs will be reduced and the vaccine’s administration will be eased.”
The researchers hope that the 3D technology will also be used to develop oral vaccines against several other types of disease. The goal of the Danish researchers’ Brazilian collaborative partners is to produce a 6-in-1 oral vaccine against diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B. The vaccine against diphtheria and tetanus is already being developed.
Learn more: Needleless vaccine will protect children from dangerous viruses
The Latest on: Oral vaccines
[google_news title=”” keyword=”oral vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Oral vaccines
- Cholera Oral Vaccine: WHO Prequalifies a New Simplified Vaccineon April 26, 2024 at 3:54 am
The World Health Organization (WHO) has prequalified a new oral cholera vaccine, a simplified formulation that will help increase its production capacity.
- Demand for the cholera vaccine is soaring – this company might have a solutionon April 25, 2024 at 9:02 am
In the global race to provide enough vaccines to tackle the ever-growing threat posed by cholera, one company is leading the field.
- Cows' milk particles used for effective oral delivery of drugson April 24, 2024 at 11:16 am
Researchers have found that tiny particles present in cows' milk could offer, for the first time, an effective method for the oral delivery of RNA drugs.
- Netherlands: Health Secy visits Bilthoven Biologicals, discusses collaboration on production of oral polio vaccineon April 24, 2024 at 7:55 am
Union Health Secretary Apurva Chandra on Wednesday visited the manufacturing unit of global pharmaceutical company Bilthoven Biologicals at Utrecht, Netherlands.
- A vaccine for bees has an unexpected effecton April 24, 2024 at 5:29 am
WASHINGTON — The first vaccine designed for insects may make honeybees healthier overall. Honeybee hives vaccinated against a bacterial disease had much lower levels of an unrelated viral disease than ...
- WHO prequalifies new oral simplified vaccine for choleraon April 23, 2024 at 1:55 am
A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO). The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines but a ...
- World Health Organization prequalifies simplified oral cholera vaccine Euvichol-Son April 22, 2024 at 4:29 am
The World Health Organization (WHO) has prequalified a new inactivated and simplified oral vaccine for cholera, Euvichol-S, to “rapidly increase” production capacity to overcome global shortages. The ...
- WHO prequalifies new simplified oral vaccine for choleraon April 22, 2024 at 12:00 am
While similar in efficacy to existing vaccines, the inactivated oral vaccine has a simplified formulation, allowing opportunities to rapidly increase production capacity ...
- WHO prequalifies new oral vaccine for cholera; Here’s what you need to knowon April 19, 2024 at 4:48 am
Euvichol-S is a simplified formulation of the oral cholera vaccine (OCV) Euvichol-Plus. The vaccine is manufactured by South Korea-based EuBiologics Co., Ltd.
- Easier-to-Make Cholera Vaccine Approved by WHO Amid Shortageon April 19, 2024 at 2:06 am
An oral vaccine for cholera that is more simple to make than existing versions has been approved by the World Health Organization in a move that is expected to rapidly increase production capacity ...
via Bing News